November 2024

Coverage from the recent Institute for Value-Based Medicine event with NYU Langone Health.

Coverage from the IVBM Regional event in Denver, Colorado.

Coverage from the IVBM event with Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Coverage from the IVBM Regional event in Boston, Massachusetts.

Institute for Value-Based Medicine event with City of Hope.

An August 2024 update to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines for treatment of myeloproliferative neoplasms (MPN) calls puts a priority on clinical trials, even preferring them to FDA-approved therapies in some cases. Aaron Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute discusses the updates and what's in the pipeline for MPN treatment.

The updated guidelines from the US Preventive Services Task Force (USPSTF) have led to an increase in screening for colorectal cancer (CRC) in individuals aged 45 to 49 years.

Hereditary breast cancers are caused by germline mutations, which are genetic mutations inherited at conception and so called because they originate in germ cells, those that develop into reproductive cells and become eggs in female individuals and sperm in male individuals.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.